Adagio Therapeutics Inc Stock

$0.79

6.47% yesterday

Nasdaq, Jun 13, 10:13 pm CET

ISIN

US00534A1025

Symbol

IVVD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Adagio Therapeutics Inc Stock price

$0.79

-16.21 95.34% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

-0.05 6.47%

ISIN

US00534A1025

Symbol

IVVD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$101.58m
Enterprise Value	$53.50m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	1.46
P/S ratio (TTM) P/S ratio	2.77
P/B ratio (TTM) P/B ratio	1.88
Revenue (TTM) Revenue	$36.69m
EBIT (operating result TTM) EBIT	$-147.71m
Free Cash Flow (TTM) Free Cash Flow	$-141.55m
Cash position	$48.08m
EPS (TTM) EPS	$-1.19
P/E forward	negative
P/S forward	0.92
EV/Sales forward	0.48
Short interest	9.11%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Adagio Therapeutics Inc forecast:

2x Buy

67%

1x Hold

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	37 37	- 100%
- Direct Costs	2.45 2.45	- 7%
Gross Profit	34 34	- 93%
- Selling and Administrative Expenses	65 65	23% 23% 178%
- Research and Development Expense	117 117	30% 30% 318%
EBITDA	-144 -144	34% 34% -394%
- Depreciation and Amortization	3.33 3.33	278% 278% 9%
EBIT (Operating Income) EBIT	-148 -148	33% 33% -403%
Net Profit	-143 -143	31% 31% -389%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adagio Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

18 days ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that results from its CANOPY Phase 3 clinical trial of pemivibart have been published online as an Advance Article in the peer-reviewed journal Clinical Infectious Diseases (CID), available here. The publication, titled “Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Preventi...

Neutral

GlobeNewsWire

●

22 days ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN joins the Infectious Disease Society of America (IDSA) that updated its COVID-19 guidelines in ...

Neutral

GlobeNewsWire

●

24 days ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally aligns with recent Invivyd Citizen Petition requests In contrast to vaccine boosters, monoclonal antibody (mAb) therapies, including pemivibart, underwent contemporary randomized, placebo-controlled ...

More Adagio Therapeutics Inc News

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office	United States
CEO	William Duke
Employees	95
Founded	2020
Website	invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now